home.social

#pompedisease — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #pompedisease, aggregated by home.social.

  1. Sanofi posts positive Nexviazyme phase 3 IOPD data | SNY SEC Filing

    About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling…
    #France #FR #Europe #EU #Sanofi #Baby-COMET #biopharma #enzymereplacementtherapy #infantile-onsetPompe #labelextension #Nexviazyme #phase3trial #Pompedisease #SNY
    europesays.com/france/47935/

  2. Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

    Sanofi Winthrop Industrie Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study…
    #France #FR #Europe #EU #Sanofi #cardiacmuscles #diseaseprogression #musclecells #Nexviazyme #participants #phase3study #Pompedisease
    europesays.com/france/46130/

  3. Sanofi aims for Nexviazyme approval in younger Pompe disease patients

    Sanofi’s Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase…
    #France #FR #Europe #EU #Sanofi #diseaseprogression #invasiveventilation #neuromusculardisease #Nexviazyme #Pompedisease
    europesays.com/france/44477/

  4. Sanofi (ENXTPA:SAN) Faces EU Antitrust Probe As Nexviazyme Trial Delivers Positive Data

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
    #France #FR #Europe #EU #Sanofi #antitrustinvestigation #EuropeanCommission #EuropeanEconomicArea #fluvaccine #Pompedisease #rarediseases #SimplyWallSt
    europesays.com/france/43941/

  5. Sanofi (ENXTPA:SAN) Faces EU Antitrust Probe As Nexviazyme Trial Delivers Positive Data

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
    #Europe #EU #antitrustinvestigation #EuropeanCommission #europeaneconomicarea #EuropeanUnion #fluvaccine #Pompedisease #rarediseases #Sanofi #SimplyWallSt
    europesays.com/europe/82995/

  6. Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

    Sanofi Winthrop Industrie Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study…
    #France #FR #Europe #EU #Sanofi #cardiacmuscles #diseaseprogression #musclecells #Nexviazyme #participants #phase3study #Pompedisease
    europesays.com/france/43634/